NCT02962739View on ClinicalTrials.gov

The Cellular Pharmacology of F-TAF in Dried Blood Spots

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

May 22, 2019

Study Completion Date

May 22, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

emtricitabine 200 mg/tenofovir alafenamide 25mg

1 tablet of Descovy contains emtricitabine 200 mg/tenofovir alafenamide 25mg

Trial Locations (1)

80045

University of Colorado- Anschutz Campus, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER

NCT02962739 - The Cellular Pharmacology of F-TAF in Dried Blood Spots | Biotech Hunter | Biotech Hunter